

## FIRST TIME GENERIC APPROVAL

<b>Brand Name</b>	Vimpat®
<b>Generic Name</b>	lacosamide
<b>Drug Manufacturer</b>	ALKEM LABS LTD

### New Drug Approval

#### TYPE OF CLINICAL UPDATE

First Time Generic

#### FDA APPROVAL DATE

March 12, 2021

#### LAUNCH DATE

N/A

#### REVIEW DESIGNATION

Standard

#### TYPE OF REVIEW

Abbreviated New Drug Application (ANDA): 214672

#### DISPENSING RESTRICTIONS

N/A

### Overview

#### INDICATION FOR USE

Lacosamide oral solution is indicated for:

- Treatment of partial-onset seizures in patients 4 years of age and older.
- Adjunctive therapy in the treatment of primary generalized tonic-clonic seizures in patients 4 years of age and older.

#### MECHANISMS OF ACTION

The precise mechanism by which lacosamide exerts its antiepileptic effects in humans remains to be fully elucidated. In vitro electrophysiological studies have shown that lacosamide selectively enhances slow inactivation of voltage-gated sodium channels, resulting in stabilization of hyperexcitable neuronal membranes and inhibition of repetitive neuronal firing.

#### DOSE FORM AND STRENGTH

10 mg/mL oral solution.

#### DOSE & ADMINISTRATION

- Adults (17 years and older)
  - Initial dosage for monotherapy for the treatment of partialonset seizures is 100 mg twice daily.

This document is designed to be an informational resource to facilitate discussion and should be used neither as a basis for clinical decision-making or treatment nor as a substitute for reading original literature. RxAdvance makes every effort to ensure that the information provided is up-to-date, accurate, and complete, but no guarantee is made to that effect. If this information is provided to clients or vendors, it is subject to any contractual confidentiality provisions. Third-party disclosures are in violation of confidentiality provisions.

## FIRST TIME GENERIC APPROVAL

- Initial dosage for adjunctive therapy for the treatment of partial-onset seizures or primary generalized tonic-clonic seizures is 50 mg twice daily.
- Maximum recommended dosage for monotherapy and adjunctive therapy is 200 mg twice daily.
- Pediatric Patients 4 years to less than 17 years: The recommended dosage is based on body weight and is administered orally twice daily.
  - Pediatric Patients 4 years to less than 17 years: The recommended dosage is based on body weight and is administered orally twice daily.

This document is designed to be an informational resource to facilitate discussion and should be used neither as a basis for clinical decision-making or treatment nor as a substitute for reading original literature. RxAdvance makes every effort to ensure that the information provided is up-to-date, accurate, and complete, but no guarantee is made to that effect. If this information is provided to clients or vendors, it is subject to any contractual confidentiality provisions. Third-party disclosures are in violation of confidentiality provisions.